Second-generation H1-antihistamines in chronic urticaria: An evidence-based review

American Journal of Clinical Dermatology

Volumn 12, Issue 6, 2011, Pages 361-376

  KavoS H , Eric R ^a   Khan, David A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Adverse drug reactions; Antihistamines; Cetirizine; Desloratadine; Evidence based medicine; Fexofenadine; Histamine H1 receptor antagonists; Levocetirizine; Loratadine; Nonsedating antihistamines; Urticaria

Indexed keywords

CETIRIZINE; DESLORATADINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HYDROXYZINE; LEVOCETIRIZINE; LORATADINE; PLACEBO; HISTAMINE; HISTAMINE H1 RECEPTOR;

ALLERGIC RHINITIS; ATOPIC DERMATITIS; CHRONIC URTICARIA; COLD URTICARIA; COMPARATIVE EFFECTIVENESS; DROWSINESS; DRUG COST; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENCY; DRUG SAFETY; DRUG SELECTIVITY; DRUG TOLERABILITY; DRUG TOLERANCE; ERYTHEMA; EVIDENCE BASED MEDICINE; FATIGUE; HEADACHE; HUMAN; PRIORITY JOURNAL; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW; XEROSTOMIA; CHRONIC DISEASE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECT; METABOLISM; URTICARIA;

CHRONIC DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; HISTAMINE; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; RECEPTORS, HISTAMINE H1; URTICARIA;

EID: 80053541411     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.2165/11591130-000000000-00000     Document Type: Review

References (61)

1. Kaplan AP. Chronic urticaria: pathogenesis and treatment. J Allergy Clin Immunol 2004 Sep; 114 (3): 465-74; quiz 475 (Pubitemid 39194914)
2. Kozel MM, Mekkes JR, Bossuyt PM, et al. Natural course of physical and chronic urticaria and angioedema in 220 patients. J Am Acad Dermatol 2001 Sep; 45 (3): 387-91 (Pubitemid 32800494)
3. Humphreys F, Hunter JA. The characteristics of urticaria in 390 patients. Br J Dermatol 1998 Apr; 138 (4): 635-8 (Pubitemid 28212248)
4. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence- based review, part 2. Ann Allergy Asthma Immunol 2008 Jun; 100 (6): 517-26; quiz 526-8, 544 (Pubitemid 351829849)
5. Morgan M, Khan DA. Therapeutic alternatives for chronic urticaria: an evidence- based review, part 1. Ann Allergy Asthma Immunol 2008 May; 100 (5): 403-11; quiz 412-4, 468
6. Leurs R, Church MK, Taglialatela M. H1-antihistamines: inverse agonism, anti-inflammatory actions and cardiac effects. Clin Exp Allergy 2002 Apr; 32 (4): 489-98 (Pubitemid 34429565)
7. Handley DA, Magnetti A, Higgins AJ. Therapeutic advantages of third generation antihistamines. Expert Opin Investig Drugs 1998 Jul; 7 (7): 1045-54 (Pubitemid 28323090)
8. Simons FE. Advances in H1-antihistamines. N Engl J Med 2004 Nov 18; 351 (21): 2203-17
9. Khan DA. Chronic urticaria: diagnosis and management. Allergy Asthma Proc 2008 Sep-Oct; 29 (5): 439-46
10. Verster JC, Volkerts ER, van Oosterwijck AW, et al. Acute and subchronic effects of levocetirizine and diphenhydramine on memory functioning, psychomotor performance, and mood. J Allergy Clin Immunol 2003 Mar; 111 (3): 623-7 (Pubitemid 36337888)
11. Kaplan AP. What the first 10,000 patients with chronic urticaria have taught me: a personal journey. J Allergy Clin Immunol 2009 Mar; 123 (3): 713-7
12. Zuberbier T, Asero R, Bindslev-Jensen C, et al. EAACI/GA(2)LEN/ EDF/WAO guideline: management of urticaria. Allergy 2009 Oct; 64 (10): 1427-43
13. Okamato T, Iwata S, Ohnuma K, et al. Histamine H1-receptor antagonists with immunomodulating activities: potential use for modulating T helper type 1 (Th1)/Th2 cytokine imbalance and inflammatory responses in allergic diseases. Clin Exp Immunol 2009; 157: 27-34
14. Gillman S, Gillard M, Strolin Benedetti M. The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1 antihistamines. Allergy Asthma Proc 2009 Jul-Aug; 30 (4): 366-76
15. Dubertret L, Murrieta Aguttes M, Tonet J. Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of theMILOR Study. J Eur Acad Dermatol Venereol 1999 Jan; 12 (1): 16-24 (Pubitemid 29132981)
16. Magerl M, Schmolke J, Metz M, et al. Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. Clin Exp Dermatol 2009 Jul; 34 (5): e137-40
17. Kalis B. Double-blind multicentre comparative study of ebastine, terfenadine and placebo in the treatment of chronic idiopathic urticaria in adults. Drugs 1996; 52 Suppl. 1: 30-4 (Pubitemid 26290227)
18. Dubertret L, Zalupca L, Cristodoulo T, et al. Once-daily rupatadine improves the symptoms of chronic idiopathic urticaria: a randomised, double-blind, placebo-controlled study. Eur J Dermatol 2007 May-Jun; 17 (3): 223-8 (Pubitemid 46847786)
19. Gimenez-Arnau A, Pujol RM, Ianosi S, et al. Rupatadine in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled multicentre study. Allergy 2007 May; 62 (5): 539-46 (Pubitemid 46608361)
20. Brozek JL, Akl EA, Alonso-Coello P, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 1 of 3. An overview of the GRADE approach and grading quality of evidence about interventions. Allergy 2009 May; 64 (5): 669-77
21. Brozek JL, Akl EA, Jaeschke R, et al. Grading quality of evidence and strength of recommendations in clinical practice guidelines: part 2 of 3. The GRADE approach to grading quality of evidence about diagnostic tests and strategies. Allergy 2009 Aug; 64 (8): 1109-16
22. Monroe EW, Fox RW, Green AW, et al. Efficacy and safety of loratadine (10 mg once daily) in the management of idiopathic chronic urticaria. J Am Acad Dermatol 1988 Jul; 19 (1 Pt 1): 138-9
23. Monroe EW, Bernstein DI, Fox RW, et al. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria. Arzneimittelforschung 1992 Sep; 42 (9): 1119-21
24. Monroe EW. Relative efficacy and safety of loratadine, hydroxyzine, and placebo in chronic idiopathic urticaria and atopic dermatitis. Clin Ther 1992 Jan-Feb; 14 (1): 17-21
25. Juhlin L. Cetirizine in the treatment of chronic urticaria. Clin Ther 1991 Jan- Feb; 13 (1): 81-6
26. Goh CL, Wong WK, Lim J. Cetirizine vs placebo in chronic idiopathic urticaria: a double blind randomised cross-over study. Ann Acad Med Singapore 1991 May; 20 (3): 328-30
27. Juhlin L, Arendt C. Treatment of chronic urticaria with cetirizine dihydrochloride a non-sedating antihistamine. Br J Dermatol 1988; 119: 67-72
28. Breneman DL. Cetirizine versus hydroxyzine and placebo in chronic idiopathic urticaria. Ann Pharmacother 1996 Oct; 30 (10): 1075-9 (Pubitemid 26332861)
29. Kalivas J, Breneman D, Tharp M, et al. Urticaria: clinical efficacy of cetirizine in comparison with hydroxyzine and placebo. J Allergy Clin Immunol 1990 Dec; 86 (6 Pt 2): 1014-8
30. Finn Jr AF, Kaplan AP, Fretwell R, et al. A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria. J Allergy Clin Immunol 1999 Nov; 104 (5): 1071-8 (Pubitemid 29532131)
31. Nelson HS, Reynolds R, Mason J. Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria. Ann Allergy Asthma Immunol 2000 May; 84 (5): 517-22 (Pubitemid 30365414)
32. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000 Jul; 43 (1 Pt 1): 24-30 (Pubitemid 30439708)
33. Kulthanan K, Gritiyarangsan P, Sitakalin C, et al. Multicenter study of the efficacy and safety of fexofenadine 60mg twice daily in 108 Thai patients with chronic idiopathic urticaria. J Med Assoc Thai 2001 Feb; 84 (2): 153-9
34. Kawashima M, Harada M. Efficacy and safety of fexofenadine HCl in Japanese patients with chronic idiopathic urticaria. Int Arch Allergy Immunol 2001; 124: 343-5 (Pubitemid 32304845)
35. Kaplan AP, Spector SL, Meeves S, et al. Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo- controlled study. Ann Allergy Asthma Immunol 2005 Jun; 94 (6): 662-9 (Pubitemid 40847153)
36. Spector SL, Shikiar R, Harding G, et al. The effect of fexofenadine hydrochloride on productivity and quality of life in patients with chronic idiopathic urticaria. Cutis 2007 Feb; 79 (2): 157-62
37. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Int J Dermatol 2001 Jan; 40 (1): 72-6 (Pubitemid 32201239)
38. Monroe E, Finn A, Patel P, et al. Efficacy and safety of desloratadine 5mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial. J Am Acad Dermatol 2003 Apr; 48 (4): 535-41 (Pubitemid 36397016)
39. Ortonne JP, Grob JJ, Auquier P, et al. Efficacy and safety of desloratadine in adults with chronic idiopathic urticaria: a randomized, double-blind, placebocontrolled, multicenter trial. Am J Clin Dermatol 2007; 8 (1): 37-42 (Pubitemid 46998562)
40. Grob JJ, Auquier P, Dreyfus I, et al. Quality of life in adults with chronic idiopathic urticaria receiving desloratadine: a randomized, double-blind, multicentre, placebo-controlled study. J Eur Acad Dermatol Venereol 2008 Jan; 22 (1): 87-93
41. Grob JJ, Auquier P, Dreyfus I, et al. How to prescribe antihistamines for chronic idiopathic urticaria: desloratadine daily vs PRN and quality of life. Allergy 2009 Apr; 64 (4): 605-12
42. Augustin M, Ehrle S. Safety and efficacy of desloratadine in chronic idiopathic urticaria in clinical practice: an observational study of 9246 patients. J Eur Acad Dermatol Venereol 2009 Mar; 23 (3): 292-9
43. Nettis E, Colanardi MC, Barra L, et al. Levocetirizine in the treatment of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study. Br J Dermatol 2006; 154: 533-8 (Pubitemid 43382664)
44. Kapp A, Pichler WJ. Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: a randomized, double-blind, placebocontrolled, parallel, multicenter study. Int J Dermatol 2006 Apr; 45 (4): 469-74
45. Aaronson DW. Evaluation of cetirizine in patients with allergic rhinitis and perennial asthma. Ann Allergy Asthma Immunol 1996 May; 76 (5): 440-6 (Pubitemid 26153156)
46. Bachert C, Bousquet J, Canonica GW, et al. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. J Allergy Clin Immunol 2004 Oct; 114 (4): 838-44 (Pubitemid 39330255)
47. DiepgenTL. Long-termtreatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol 2002 Aug; 13 (4): 278-86 (Pubitemid 35231044)
48. Guerra L, Vincenzi C, Marchesi E, et al. Loratadine and cetirizine in the treatment of chronic urticaria. J Eur Acad Dermatol Venereol 1994; 3 (2): 148-52 (Pubitemid 24135689)
49. Handa S, Dogra S, Kumar B. Comparative efficacy of cetirizine and fexofenadine in the treatment of chronic idiopathic urticaria. JDermatolog Treat 2004 Jan; 15 (1): 55-7 (Pubitemid 38252098)
50. Garg G, Thami GP. Comparative efficacy of cetirizine and levocetirizine in chronic idiopathic urticaria. J Dermatolog Treat 2007; 18 (1): 23-4 (Pubitemid 46410637)
51. Potter PC, Kapp A, Maurer M, et al. Comparison of the efficacy of levocetirizine 5mg and desloratadine 5mg in chronic idiopathic urticaria patients. Allergy 2009 Apr; 64 (4): 596-604
52. Staevska M, Popov TA, Kralimarkova T, et al. The effectiveness of levocetirizine and desloratadine in up to 4 times conventional doses in difficult-totreat urticaria. J Allergy Clin Immunol 2010 Mar; 125 (3): 676-82
53. Anuradha P, Maiti R, Jyothirmai J, et al. Loratadine versus levocetirizine in chronic idiopathic urticaria: a comparative study of efficacy and safety. Indian J Pharmacol 2010 Feb; 42 (1): 12-6
54. Asero R. Chronic unremitting urticaria: is the use of antihistamines above the licensed dose effective? A preliminary study of cetirizine at licensed and above-licensed doses. Clin Exp Dermatol 2007 Jan; 32 (1): 34-8 (Pubitemid 46006362)
55. Kameyoshi Y, Tanaka T,Mihara S, et al. Increasing the dose of cetirizine may lead to better control of chronic idiopathic urticaria: an open study of 21 patients. Br J Dermatol 2007 Oct; 157 (4): 803-4 (Pubitemid 47389865)
56. Siebenhaar F, Degener F, Zuberbier T, et al. High-dose desloratadine decreases wheal volume and improves cold provocation thresholds compared with standarddose treatment in patients with acquired cold urticaria: a randomized, placebocontrolled, crossover study. J Allergy Clin Immunol 2009 Mar; 123 (3): 672-9
57. Zuberbier T, Aberer W, Burtin B, et al. Efficacy of cetirizine in cholinergic urticaria. Acta Derm Venereol 1995 Mar; 75 (2): 147-9
58. Zuberbier T,Munzberger C, Haustein U, et al. Double-blind crossover study of high-dose cetirizine in cholinergic urticaria. Dermatology 1996; 193 (4): 324-7 (Pubitemid 27007577)
59. Juhlin L. Inhibition of cold urticaria by desloratadine. J Dermatolog Treat 2004 Jan; 15 (1): 51-9
60. Kontou-Fili K, Maniatakou G, Demaka P, et al. Therapeutic effects of cetirizine in delayed pressure urticaria: part 1. Effects on weight tests and skinwindow cytology. Ann Allergy 1990 Dec; 65 (6): 517-9
61. Kontou-Fili K,Maniatakou G, Paleologos G, et al. Cetirizine inhibits delayed pressure urticaria: part 2. Skin biopsy findings. Ann Allergy 1990 Dec; 65 (6): 520-2